(Q35852289)

10 August 2017

1 reference

title

A new oral anticoagulant: the 50-year challenge (English)

1 reference

10 August 2017

1 reference

1 reference

7

Ulf Bredberg

1 reference

10 August 2017

David Gustafsson

1

1 reference

10 August 2017

Ruth Bylund

2

1 reference

10 August 2017

Thomas Antonsson

3

1 reference

10 August 2017

Ingemar Nilsson

4

1 reference

10 August 2017

Jan-Erik Nyström

5

1 reference

10 August 2017

Ulf Eriksson

6

1 reference

10 August 2017

Ann-Catrine Teger-Nilsson

8

1 reference

10 August 2017

language of work or name

1 reference

1 August 2004

1 reference

Nature Reviews Drug Discovery

10 August 2017

published in

1 reference

10 August 2017

volume

3

1 reference

10 August 2017

issue

8

1 reference

10 August 2017

page(s)

649-659

1 reference

The discovery of dicumarol and its sequels

10 August 2017

cites work

1 reference

Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century

21 January 2018

1 reference

Dissociation of hospitalization and mortality trends for myocardial infarction in the United States from 1988 to 1997.

31 March 2020

1 reference

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

31 March 2020

1 reference

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range

31 March 2020

1 reference

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

31 March 2020

1 reference

31 March 2020

1 reference

31 March 2020

Thrombin interactions

1 reference

The clotting of fibrinogen. II. Fractionation of peptide material liberated

31 March 2020

1 reference

D-PHE-PRO-ARGCH2Cl-A selective affinity label for thrombin

31 March 2020

1 reference

Inhibition of thrombin and trypsin by tripeptide aldehydes

31 March 2020

1 reference

Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion

31 March 2020

1 reference

An overview of the direct thrombin inhibitor argatroban

31 March 2020

1 reference

Advances in the development of thrombin inhibitors

31 March 2020

1 reference

The development of hirudin as an antithrombotic drug

31 March 2020

1 reference

Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions

31 March 2020

1 reference

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

31 March 2020

1 reference

In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor

31 March 2020

1 reference

Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug

31 March 2020

1 reference

Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat

31 March 2020

1 reference

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans

31 March 2020

1 reference

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

31 March 2020

1 reference

Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments

31 March 2020

1 reference

Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats

31 March 2020

1 reference

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects

31 March 2020

1 reference

Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions

31 March 2020

1 reference

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

31 March 2020

1 reference

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study

31 March 2020

1 reference

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

31 March 2020

1 reference

Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia.

31 March 2020

1 reference

Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran

31 March 2020

1 reference

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

31 March 2020

1 reference

Oral direct thrombin inhibitors in clinical development

31 March 2020

1 reference

High-resolution NMR studies of fibrinogen-like peptides in solution: structure of a thrombin-bound peptide corresponding to residues 7-16 of the A alpha chain of human fibrinogen

31 March 2020

1 reference

The interaction of thrombin with fibrinogen. A structural basis for its specificity

31 March 2020

1 reference

The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review

31 March 2020

1 reference

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

31 March 2020

1 reference

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

31 March 2020

1 reference

No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

31 March 2020

1 reference

Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects

31 March 2020

1 reference

Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis

31 March 2020

1 reference

Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran

31 March 2020

1 reference

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD1466

1 reference

10 August 2017

1 reference